New hope for brain cancer? experimental drug combo tested in early trial
NCT ID NCT05635734
First seen Feb 05, 2026 · Last updated Apr 28, 2026 · Updated 12 times
Summary
This early-phase study tests whether adding the experimental drug azeliragon to standard radiation and chemotherapy (temozolomide) is safe for people with newly diagnosed glioblastoma, an aggressive brain cancer. About 18 participants will receive the combination to find the best dose and look for early signs that the tumor shrinks or stops growing. The goal is to control the disease, not cure it, as ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Clínic de Barcelona
Barcelona, Barcelona, 08036, Spain
-
Hospital Universitario 12 de Octubre
Madrid, Madrid, 28041, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, Madrid, 28034, Spain
-
Hospital del Mar
Barcelona, Barcelona, 08003, Spain
Conditions
Explore the condition pages connected to this study.